Skip to content

Expressive Writing in Improving Quality of Life in Patients With Breast Cancer and Lymphedema

Effects of Expressive Writing in Breast Cancer Survivors With Lymphedema

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00679185
Enrollment
107
Registered
2008-05-16
Start date
2007-01-31
Completion date
2011-01-31
Last updated
2017-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Fatigue, Lymphedema

Keywords

fatigue, stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, lymphedema

Brief summary

RATIONALE: Expressive writing may help relieve symptoms and improve quality of life in breast cancer survivors with chronic lymphedema. PURPOSE: This clinical trial is studying expressive writing in improving the quality of life in women with breast cancer and lymphedema.

Detailed description

OBJECTIVES: Primary * To determine if expressive writing improves quality of life (QOL) relative to the control condition in breast cancer survivors with chronic stage II lymphedema. * To determine if expressive writing improves physical and psychological symptoms/outcomes (i.e., fatigue, psychological distress, activity level, confidence in body) relative to the control condition in breast cancer survivors with chronic lymphedema. Secondary * To explore the influence of individual difference variables (dispositional optimism, emotional intelligence, and repressive coping) on outcomes associated with this intervention to include identification of subsets of individuals for whom expressive writing is most effective. * To explore the influence of intrusive/avoidant thinking as a mediator between the intervention and outcomes of QOL and physical and psychological symptoms. OUTLINE: Patients are randomized to 1 of 2 treatment groups. Patients travel to the School of Nursing at Vanderbilt University or meet a team member in their home or another private location for an initial visit. Patients complete questionnaires, are measured for height and weight data, and arm fluid measurements. * Expressive writing group: Twenty minutes a day, twice a week for 2 weeks, patients write about their deepest thoughts and feelings regarding their lymphedema and its treatment. * Daily diary group (control): Twenty minutes a day, twice a week for 2 weeks patients write about how they manage their time . Patients complete quality-of-life questionnaires periodically. After completion of study, patients are followed at 1, 3, and 6 months.

Interventions

BEHAVIORALexpressive writing

four non-emotional writing assignments

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Vanderbilt University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Women who have undergone prior surgery and/or radiotherapy for breast cancer * No metastatic disease * Must have lymphedema, meeting the following conditions: * Stage II disease * Swelling unrelieved by elevation, arm may be hard, may not pit with pressure, or skin changes have taken place * Received prior professional treatment for lymphedema * Requires life-long, at home self-care (e.g., compression sleeves) * No history of bilateral lymphedema prohibiting extracellular fluid comparison to an unaffected limb PATIENT CHARACTERISTICS: Inclusion criteria: * Able to read, write (for 20 minutes), and speak English * Willing and able to drive to the study site or agree to be seen in an outpatient setting (e.g., private therapist office, outpatient clinic, physicians office, or own home) once

Exclusion criteria

* Has medical condition that could cause edema, including any of the following: * Symptomatic congestive heart failure * Chronic/acute renal disease * Cor pulmonale * Nephrotic syndrome * Nephrosis * Liver failure * Cirrhosis * Pregnant or expect to become pregnant during course of the study * Unable to stand upright for measurement of height and weight * Has a metal implant, internal defibrillator, or pacemakers * History of suicide attempts * No recent suicidal ideation (within last 6 months) PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No concurrent intravenous chemotherapy or radiotherapy for active cancer * No concurrent antipsychotic medication (i.e., haldol, thorazine, stelazine)

Design outcomes

Primary

MeasureTime frame
Quality of life6 months
Psychological distress6 months
Activity level6 months
Physical and psychological symptoms6 months
Fatigue6 months

Secondary

MeasureTime frame
Influence of individual difference variables to discover subsets for treatment effectivenessbaseline study entry
Influence of intrusive/avoidant thinking in quality of life and physical or psychological symptomsbaseline study entry

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026